Rubric Capital Management LP bought $3.6M of HRTX
owner at HERON THERAPEUTICS, INC. /DE/. 2,387,225 shares at an average of $1.50, traded Aug 8, 2025, filed Aug 12, 2025.
Score components
- +12Role10% owner
- +25Trade size$3.6M at market
- +3Relative to holdingsHoldings up 9%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.3%, 3m -11.5%, 6m -3.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-25-003535, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | POpen-market purchase Common Stock, par value $0.01 per share ("Common Stock")indirect: See footnotes | +2,387,225 | $1.50 | $3.6M | 29,100,728 | Aug 12, 2025 |
| Aug 8, 2025 | POpen-market purchase Convertible Senior Unsecured Promissory Notes ("Notes")derivativeindirect: See footnotes | - | $33,250,000.00 | - | - | Aug 12, 2025 |
| Aug 8, 2025 | POpen-market purchase Series A Convertible Preferred Stock ("Preferred Shares")derivativeindirect: See footnotes | +94,610 | $15.00 | $1.4M | 94,610 | Aug 12, 2025 |
Related signals
Other insiders at HERON THERAPEUTICS, INC. /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | HERON THERAPEUTICS, INC. /DE/ | Adam Morgan director | $2.6M 1,766,546 shares | +25% | |
| 54Moderate | HERON THERAPEUTICS, INC. /DE/ | William P Forbes EVP, Chief Development Officer | $27k 25,000 shares | +46% | |
| 54Moderate | HERON THERAPEUTICS, INC. /DE/ | William P Forbes EVP, Chief Development Officer | $47k 50,000 shares | +1250% | |
| 69Notable | HERON THERAPEUTICS, INC. /DE/ | Craig A Collard Chief Executive Officer | $138k 150,000 shares | +411% | |
| 61Notable | HERON THERAPEUTICS, INC. /DE/ | Ira Duarte EVP, Chief Financial Officer | $76k 85,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.